What are the current guidelines for diagnosing and managing intra‑hepatic cholestasis of pregnancy, including laboratory evaluation, treatment options, fetal monitoring, and timing of delivery?

Obstetric Cholestasis: Comprehensive Guideline Summary

Diagnosis

Diagnose intrahepatic cholestasis of pregnancy (ICP) when serum total bile acids exceed 10 μmol/L in the presence of pruritus, typically occurring in the late second or third trimester. 1

Clinical Presentation

• Pruritus is generalized, predominantly affects palms and soles, worsens at night, and occurs without a primary rash—only excoriations from scratching may be visible. 1, 2
• Onset typically occurs after 30 weeks' gestation in approximately 80% of cases, though earlier presentation (second trimester) may indicate more severe disease. 1
• Jaundice is uncommon, occurring in only 10–15% of cases with bilirubin levels typically remaining below 5 mg/dL; dark urine and jaundice should prompt immediate evaluation for HELLP syndrome or acute fatty liver of pregnancy. 1

Laboratory Evaluation

• Order random (non-fasting) serum total bile acids and liver transaminases (ALT/AST) immediately in any pregnant woman presenting with new-onset pruritus in the second or third trimester. 1, 2
• Bile acids >10 μmol/L confirm the diagnosis when accompanied by pruritus. 1, 3
• Liver transaminases are elevated in most cases but are not required for diagnosis; levels are typically <500 U/L in ICP. 1
• Use enzymatic bile acid assays (results in 4 hours to 4 days) rather than mass spectrometry (4–14 days) when rapid turnaround is needed. 1
• If initial bile acids are normal but pruritus persists, repeat testing in 1–2 weeks, as bile acid elevation can lag behind symptom onset by several weeks. 1

Differential Diagnosis

• Immediately exclude preeclampsia/HELLP syndrome and acute fatty liver of pregnancy in any patient with elevated liver enzymes, as these conditions carry significant maternal mortality risk and require immediate delivery. 1
• HELLP syndrome is characterized by hemolysis, elevated liver enzymes, and low platelets (occurs in 0.2–0.6% of pregnancies). 1
• Acute fatty liver of pregnancy presents with elevated liver enzymes and bilirubin in the third trimester (occurs in 0.005–0.01% of pregnancies). 1
• Consider non-pregnancy causes: primary biliary cholangitis, primary sclerosing cholangitis, ABCB4 deficiency, renal disease, thyroid disorders, and drug-induced cholestasis. 1
• Perform hepatobiliary ultrasound to exclude gallstones and biliary obstruction. 1

---

Pharmacologic Management

Initiate ursodeoxycholic acid (UDCA) at 10–15 mg/kg/day in 2–3 divided doses immediately after confirming bile acids >10 μmol/L (GRADE 1A). 1, 2

UDCA Therapy

• UDCA reduces maternal pruritus, lowers bile acid concentrations, decreases the risk of spontaneous preterm birth, and may reduce stillbirth risk. 1, 2
• If pruritus remains uncontrolled at the standard dose, titrate UDCA up to 21–25 mg/kg/day. 1, 2
• Discontinue UDCA at delivery or taper gradually over 2–4 weeks postpartum if pruritus persists. 1, 4

Second-Line Adjunctive Therapy for Refractory Pruritus

• Add cholestyramine 4–16 g daily in divided doses, ensuring a 2–4 hour separation from UDCA and other medications to avoid binding interactions. 2
• Monitor prothrombin time regularly when using cholestyramine and supplement vitamin K if coagulation becomes prolonged, as the resin can exacerbate vitamin K deficiency. 2
• Consider rifampin 300–600 mg daily as a second-line agent; however, it carries up to a 12% risk of drug-induced hepatitis in cholestatic patients and requires hepatic monitoring. 2
• S-adenosyl-L-methionine (SAMe) 1,000–1,200 mg daily may be used as an alternative adjunct. 2
• Antihistamines provide minimal benefit and may be trialed only for nighttime symptom relief. 2

---

Fetal Surveillance

Begin antenatal fetal testing at the gestational age when delivery would be indicated for abnormal results, or immediately if ICP is diagnosed later in pregnancy. 1

• For bile acids ≥100 μmol/L, perform at least twice-weekly fetal monitoring because stillbirth hazard increases approximately 30-fold. 1
• Increase testing frequency as bile acid levels rise. 1
• Apply continuous fetal monitoring during labor for all women with ICP, as fetal demise can occur suddenly even after recent reassuring testing. 1
• Do not initiate routine antenatal surveillance in patients with pruritus but persistently normal bile acid concentrations, as evidence does not show increased fetal risk in this subgroup. 1

---

Delivery Timing (Risk-Stratified by Peak Bile Acid Level)

Delivery timing is determined strictly by peak total bile acid levels to balance stillbirth risk against prematurity-related morbidity. 1

Severe ICP (Bile Acids ≥100 μmol/L)

• Deliver at 36 0/7 weeks' gestation (GRADE 1B). 1, 3
• Stillbirth risk rises approximately 30-fold after 35 weeks at this threshold. 1
• Administer antenatal corticosteroids for fetal lung maturity if not already given. 1

Moderate ICP (Bile Acids 40–99 μmol/L)

• Deliver between 36 0/7 and 39 0/7 weeks, favoring the earlier end of the window (GRADE 1C). 1, 3
• This range is associated with increased risks: preterm birth (RR 2.23), respiratory distress syndrome (RR 1.67), and meconium-stained amniotic fluid (RR 2.27). 1

Mild ICP (Bile Acids <40 μmol/L)

• Deliver between 37 0/7 and 39 0/7 weeks; targeting 39 weeks is reasonable given minimal stillbirth risk (~0.1%). 1, 5

Critical Pitfall

• Do NOT deliver before 37 weeks based solely on clinical suspicion without documented elevated bile acids (GRADE 1B), to avoid unnecessary prematurity-related morbidity. 1, 2

---

Maternal Monitoring

• Measure serum bile acids at least weekly from 32 weeks' gestation until delivery, as concentrations can rise rapidly and directly guide delivery timing. 1, 2
• Screen for preeclampsia; ICP is associated with a 2.6-fold increased risk (adjusted OR 2.62). 1
• Monitor for spontaneous preterm labor; elevated bile acids activate myometrial oxytocin receptors, conferring a pooled relative risk of 2.23 for preterm labor. 1

---

Postpartum Follow-Up

Repeat serum bile acids and liver transaminases at 4–6 weeks postpartum to confirm resolution of ICP. 1, 2, 4

• Pruritus typically resolves within days to weeks after delivery, and biochemical abnormalities should normalize within 4–6 weeks postpartum. 4
• If symptoms or laboratory abnormalities persist beyond 6 weeks postpartum, refer to hepatology for evaluation of underlying chronic hepatobiliary disease (e.g., primary biliary cholangitis, primary sclerosing cholangitis, ABCB4 deficiency, chronic hepatitis C). 1, 4
• Persistence beyond 6 weeks suggests the pregnancy may have unmasked an underlying chronic liver condition rather than isolated ICP. 4

---

Genetic Considerations & Long-Term Risks

• Consider genetic testing for ABCB11, ABCB4, or ATP8B1 mutations in cases with early-onset disease (second trimester), severe bile acid elevation (≥100 μmol/L), marked hyperbilirubinemia, or a family history of hepatobiliary disease. 1, 4
• Recurrence risk in subsequent pregnancies ranges from 40% to 90%, reflecting strong genetic susceptibility. 1, 6
• Women with a history of ICP have markedly elevated long-term risks: chronic hepatitis (HR 5.96), liver fibrosis/cirrhosis (HR 5.11), hepatitis C (HR 4.16), and cholangitis (HR 4.20). 1, 2

---

Key Clinical Pitfalls to Avoid

• Never assume ICP without excluding HELLP syndrome and acute fatty liver of pregnancy, as these conditions require immediate delivery and carry maternal mortality risk. 1
• A single normal bile acid measurement does not exclude ICP if pruritus persists; repeat testing in 1–2 weeks is essential. 1
• Do not mistake excoriations from scratching for a primary dermatologic rash; ICP is not associated with a primary rash. 1
• Normal fetal testing does not eliminate stillbirth risk, as ICP-related stillbirth occurs suddenly through a non-placental mechanism, making traditional fetal surveillance less predictive. 1